title: Nuclear expression of β-catenin predicts the efficacy of meloxicam treatment for patients with sporadic desmoid tumors.
abstract: This study aimed to determine the prevalence of β-catenin nuclear positivity as a prognostic factor in patients with desmoid tumors (DTs) treated with meloxicam, a cyclooxygenase-2 (COX-2) selective inhibitor. Between 2003 and 2012, consecutive 31 patients with extraabdominal, sporadic DTs were prospectively treated with meloxicam as a systemic medical therapy. Immunohistochemistry was performed on formalin-fixed material to quantify the nuclear expression of β-catenin and Ki-67, and cytoplasmic expression of COX-2. All clinicopathological characteristics including the intensity of immunohistochemical staining were analyzed with respect to their prognostic value for meloxicam treatment. Of the 31 patients with meloxicam treatment, there was 1 with complete remission (CR), 7 with partial remission (PR), 12 with stable disease (SD), and 11 with progressive disease (PD). Higher nuclear expression of β-catenin was significantly associated with a poor response (PD/SD) (p = 0.017). The positivity of COX-2 and Ki-67 and none of the other clinical variables were associated with prognosis. The nuclear expression of β-catenin can predict the efficacy of meloxicam treatment for patients with sporadic DTs.
authors.affiliation: Department of Orthopedic Surgery, Nagoya University Graduate School and School of Medicine, 65 Tsurumai, Showa, Nagoya, Aichi, 466-8550, Japan.
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Hamada
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Urakawa
authors.forename: Eiji
authors.initials: E
authors.lastname: Kozawa
authors.forename: Naohisa
authors.initials: N
authors.lastname: Futamura
authors.forename: Kunihiro
authors.initials: K
authors.lastname: Ikuta
authors.forename: Yoshie
authors.initials: Y
authors.lastname: Shimoyama
authors.forename: Shigeo
authors.initials: S
authors.lastname: Nakamura
authors.forename: Naoki
authors.initials: N
authors.lastname: Ishiguro
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Nishida
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002467:Cell Nucleus / Q000737:chemistry*; D002648:Child; D051546:Cyclooxygenase 2 / Q000032:analysis; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use*; D005260:Female; D018222:Desmoid Tumors / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000032:analysis; D008297:Male; D000077239:Meloxicam; D008875:Middle Aged; D013843:Thiazines / Q000627:therapeutic use*; D013844:Thiazoles / Q000627:therapeutic use*; D051176:beta Catenin / Q000032:analysis*
chemical_list: C495270:CTNNB1 protein, human; D052246:Cyclooxygenase 2 Inhibitors; D019394:Ki-67 Antigen; D013843:Thiazines; D013844:Thiazoles; D051176:beta Catenin; D051546:Cyclooxygenase 2; D000077239:Meloxicam